Vong Long Binh, Yoshitomi Toru, Morikawa Kazuya, Saito Shinji, Matsui Hirofumi, Nagasaki Yukio
Department of Materials Science, Graduate School of Pure and Applied Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki, 305-8573, Japan.
J Gastroenterol. 2014 May;49(5):806-13. doi: 10.1007/s00535-013-0836-8. Epub 2013 May 29.
Patients with ulcerative colitis (UC) exhibit overproduction of reactive oxygen species (ROS) and imbalance of colonic microflora. We previously developed a novel redox nanoparticle (RNP(O)), which effectively scavenged ROS in the inflamed mucosa of mice with dextran sodium sulfate (DSS)-induced colitis after oral administration. The objective of this study was to examine whether the orally administered RNP(O) changed the colonic microflora in healthy mice and those with colitis.
RNP(O) was synthesized by self-assembly of an amphiphilic block copolymer that contains stable nitroxide radicals in hydrophobic side chain via ether linkage. Colitis was induced in mice by supplementing DSS in drinking water for 7 days, and RNP(O) was orally administered daily during DSS treatment. The alterations of fecal microflora during treatment of DSS and RNP(O) were investigated using microbiological assays.
We investigated that RNP(O) did not result in significant changes to the fecal microflora in healthy mice. Although total aerobic and anaerobic bacteria were not significantly different between experimental groups, a remarkable increase in commensal bacteria (Escherichia coli and Staphylococcus sp.) was observed in mice with DSS-induced colitis. Interestingly, orally administered RNP(O) remarkably reduced the rate of increase of these commensal bacteria in mice with colitis.
On the basis of the obtained results, it was confirmed that the oral administration of RNP(O) did not change any composition of bacteria in feces, which strongly suggests a protective effect of RNP(O) on healthy environments in intestinal microflora. RNP(O) may become an effective and safe medication for treatment of UC.
溃疡性结肠炎(UC)患者表现出活性氧(ROS)过度产生以及结肠微生物群失衡。我们之前开发了一种新型氧化还原纳米颗粒(RNP(O)),口服给药后,它能有效清除葡聚糖硫酸钠(DSS)诱导的小鼠结肠炎炎症黏膜中的ROS。本研究的目的是检查口服RNP(O)是否会改变健康小鼠和结肠炎小鼠的结肠微生物群。
RNP(O)通过两亲性嵌段共聚物自组装合成,该共聚物在疏水侧链中通过醚键连接含有稳定的氮氧自由基。通过在饮用水中添加DSS 7天诱导小鼠患结肠炎,并在DSS治疗期间每天口服RNP(O)。使用微生物学检测方法研究DSS和RNP(O)治疗期间粪便微生物群的变化。
我们研究发现RNP(O)不会导致健康小鼠粪便微生物群发生显著变化。尽管实验组之间需氧菌和厌氧菌总数没有显著差异,但在DSS诱导的结肠炎小鼠中观察到共生菌(大肠杆菌和葡萄球菌属)显著增加。有趣的是,口服RNP(O)显著降低了结肠炎小鼠中这些共生菌的增加速率。
基于所得结果,证实口服RNP(O)不会改变粪便中任何细菌的组成,这强烈表明RNP(O)对肠道微生物群健康环境具有保护作用。RNP(O)可能成为治疗UC的一种有效且安全的药物。